Literature DB >> 18694528

The European Sero-Epidemiology Network 2 (ESEN2): standardization of assay results for hepatitis A virus (HAV) to enable comparisons of seroprevalence data across 15 countries.

C G Anastassopoulou1, G Kafatos, A Nardone, N Andrews, R G Pebody, J Mossong, I Davidkin, D Gelb, F DE Ory, W Thierfelder, V Nemecek, B Bruzzone, D Butur, C Barbara, Z Sobotová, L Jones, A Griskevicius, L M Hesketh, D Cohen, R Vranckx, A Tsakris, E Miller, A Hatzakis.   

Abstract

The European Sero-Epidemiology Network 2 (ESEN2) aimed to compare serological results of vaccine-preventable diseases across Europe. To ensure direct inter-country comparability of hepatitis A virus antibody (anti-HAV) measurements, a standardization panel of 150 sera was developed by a designated reference laboratory and tested by participating national laboratories using assays of choice; each country's results were subsequently regressed against those of the reference laboratory. Quantitatively, the assays were generally highly correlated (R2>0.90). Nevertheless, qualitative comparisons indicated that results obtained with different assays may differ despite the usage of well-established international and local standards. To a great extent standardization successfully alleviated such differences. The generated standardization equations will be used to convert national serological results into common units to enable direct international comparisons of HAV seroprevalence data. The results of this study are expected to contribute to the evaluation and potential improvement of the currently employed immunization strategies for hepatitis in Europe.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18694528     DOI: 10.1017/S0950268808001155

Source DB:  PubMed          Journal:  Epidemiol Infect        ISSN: 0950-2688            Impact factor:   2.451


  6 in total

1.  Seroprevalence of pertussis in China: need to improve vaccination strategies.

Authors:  Yinghua Xu; Lichan Wang; Jin Xu; Xinjian Wang; Chen Wei; Peng Luo; Xiao Ma; Qiming Hou; Junzhi Wang
Journal:  Hum Vaccin Immunother       Date:  2013-09-09       Impact factor: 3.452

2.  Prevalence of antibodies against hepatitis A virus among children and adolescents in Germany.

Authors:  A Krumbholz; A Neubert; H Girschick; H I Huppertz; P Kaiser; J Liese; A Streng; T Niehues; J Peters; A Sauerbrey; H Schroten; T Tenenbaum; S Wirth; A Sauerbrei
Journal:  Med Microbiol Immunol       Date:  2013-06-29       Impact factor: 3.402

3.  Comparative hepatitis A seroepidemiology in 10 European countries.

Authors:  S Kurkela; R Pebody; G Kafatos; N Andrews; C Barbara; B Bruzzone; D Butur; S Caplinskas; I Davidkin; A Hatzakis; W Hellenbrand; L M Hesketh; A Nardone; V Nemecek; A Pistol; Z Sobotová; R Vranckx; C G Anastassopoulou
Journal:  Epidemiol Infect       Date:  2012-01-25       Impact factor: 4.434

4.  Estimating seroprevalence of vaccine-preventable infections: is it worth standardizing the serological outcomes to adjust for different assays and laboratories?

Authors:  G Kafatos; N Andrews; K J McConway; C Anastassopoulou; C Barbara; F De Ory; K Johansen; J Mossong; K Prosenc; R Vranckx; A Nardone; R Pebody; P Farrington
Journal:  Epidemiol Infect       Date:  2014-11-25       Impact factor: 4.434

5.  The Israel National Sera Bank: Methods, Representativeness, and Challenges.

Authors:  Ravit Bassal; Dani Cohen; Manfred S Green; Lital Keinan-Boker
Journal:  Int J Environ Res Public Health       Date:  2021-02-25       Impact factor: 3.390

Review 6.  Serology as a Tool to Assess Infectious Disease Landscapes and Guide Public Health Policy.

Authors:  Andrea H Haselbeck; Justin Im; Kristi Prifti; Florian Marks; Marianne Holm; Raphaël M Zellweger
Journal:  Pathogens       Date:  2022-06-27
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.